CEL SCI CORP Logo

CEL SCI CORP

Develops immunotherapies for cancer, autoimmune, and infectious diseases.

CVM | US

Overview

Corporate Details

ISIN(s):
US1508377066
LEI:
Country:
United States of America
Address:
8229 BOONE BLVD ., 22182 VIENNA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CEL-SCI Corporation is a clinical-stage biotechnology company specializing in the research and development of immunotherapy products for the treatment of cancer, autoimmune diseases, and infectious diseases. The company's lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a pre-surgical treatment for advanced primary head and neck cancer. Its core therapeutic strategy is to activate the patient's immune system before standard treatments like surgery, chemotherapy, or radiation weaken it. A pivotal Phase III study showed Multikine provided a significant 5-year survival benefit. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) platform for autoimmune and infectious diseases, including a potential treatment for Rheumatoid Arthritis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CEL SCI CORP filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CEL SCI CORP

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CEL SCI CORP via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America
ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America
ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030

Talk to a Data Expert

Have a question? We'll get back to you promptly.